Product Description

🔹 Product Overview
CYRAMZA Injection is a prescription anticancer medicine used in the treatment of certain types of advanced or metastatic cancers. It contains Ramucirumab, a targeted therapy belonging to the class of vascular endothelial growth factor receptor 2 (VEGFR2) antagonists. It works by blocking signals that help tumors develop new blood vessels, which may slow tumor growth and progression.
CYRAMZA is administered as an intravenous infusion under the supervision of an experienced oncologist or healthcare professional. It is available as a single-dose vial formulation containing ramucirumab.

🔹 Key Uses
CYRAMZA may be prescribed for the treatment of:
Advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma
Metastatic non-small cell lung cancer (NSCLC) in specific treatment settings
Metastatic colorectal cancer in combination with appropriate chemotherapy regimens
Hepatocellular carcinoma (liver cancer) in eligible patients
Other cancer treatment protocols as determined by an oncology specialist

🔹 Composition
Active Ingredient:
Ramucirumab
Drug Class:
Monoclonal Antibody
VEGFR2 Antagonist
Targeted Cancer Therapy
Dosage Form:
Concentrate for Intravenous Infusion
Available Strengths:
Ramucirumab 100 mg/10 ml vial
Ramucirumab 500 mg/50 ml vial

🔹 How It Works
CYRAMZA contains Ramucirumab, a monoclonal antibody that specifically binds to VEGFR2 (vascular endothelial growth factor receptor 2). By blocking VEGFR2 activation, it reduces tumor-related blood vessel formation (angiogenesis).
This action may decrease the blood supply available to cancer cells, helping slow tumor growth and disease progression.

🔹 Key Benefits
Targeted therapy for selected advanced cancers
Helps inhibit tumor blood vessel formation
Used as part of specialized oncology treatment plans
May improve disease control in eligible patients
Can be used alone or with chemotherapy depending on cancer type
Administered under controlled medical supervision

🔹 Dosage and Administration
CYRAMZA should only be administered by trained healthcare professionals.
Given as an intravenous infusion after dilution.
Dose and treatment schedule depend on:
Type of cancer
Body weight
Previous treatments
Overall health condition
Patients require regular monitoring during therapy.
Pre-medication may be recommended before infusion to reduce infusion-related reactions.

🔹 Possible Side Effects
Common side effects may include:
High blood pressure
Fatigue
Diarrhea
Headache
Reduced appetite
Nausea
Swelling (edema)
Nosebleeds
Low blood cell counts
Protein in urine
Serious risks may include:
Severe bleeding
Gastrointestinal perforation
Blood clot-related complications
Infusion-related reactions
Problems with wound healing

🔹 Precautions
Before starting CYRAMZA treatment, inform your doctor if you have:
A history of bleeding problems
High blood pressure
Recent surgery or planned surgery
Liver problems
Blood clotting disorders
Kidney problems
Any ongoing infections
Additional monitoring may include:
Blood pressure checks
Urine protein testing
Blood tests
Assessment of treatment response